Interaction trial between artemether-lumefantrine (Riamet®) and quinine in healthy subjects

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1147-1158

  Lefèvre, Gilbert ^a   Carpenter, Polly ^b   Souppart, Claire ^b   Schmidli, Heinz ^a   Martin, John M ^b   Lane, Andrew ^c   Ward, Chris ^c   Amakye, Dereck ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Covance Clinical Research Unit Ltd ^*

^c 206 Carnegie Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; CIMETIDINE; DIHYDROARTEMISININ; EFAXAL; HALOFANTRINE; MEFLOQUINE; PLACEBO; PROCHLORPERAZINE; QUININE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HUMAN; MALARIA FALCIPARUM; MALE; NAUSEA; NORMAL HUMAN; PAIN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; VERTIGO;

EID: 0036785445     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382632     Document Type: Article

References (67)

1. von Seidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli B, et al: Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997;176:1113-1116.
2. Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T: Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand: a preliminary report. Southeast Asian J Trop Med Public Health 1991;22:380-385.
3. Karbwang J, Bangchang K, Thanavibul A, Back D, Bunnag D, Harinasuta T: Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull World Health Organ 1994;72:83-87.
4. White NJ: The treatment of malaria. N Engl J Med 1996;335:800-806.
5. Lefèvre G, Thomsen MS: Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Invest 1999;18:467-480.
6. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen M: Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000;10:141-151.
7. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998;46:553-561.
8. Skelton-Stroud P, Mull R, The Novartis Co-artemether International Development Team: Positioning, labelling, and medical information control of co-artemether tablets (CGP 56697): a fixed novel combination of artemether and benflumetol. Med Trop 1998;58:77S-81S.
9. WHO Drug Information. Essential Drugs, WHO Model List (revised December 1999), volume 262, 1999.
10. World Health Organization: The use of essential drugs. Ninth report of the WHO Expert Committee, WHO Technical Report Series, no. 895. Geneva, Switzerland: World Health Organization, 2000.
11. White NJ: Assessments of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:638-644.
12. White NJ: Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998;1:3-9.
13. Ambroise-Thomas P: Current data on major novel antimalaria drugs: artemisinin (qinghaosu) derivatives. Bull Acad Natl Med 1999;183:797-800.
14. Peters W, Robinson BL: The chemotherapy of rodent malaria: LVIII. Drug combinations to impede the selection of drug resistance, part 2: The new generation-artemisinin or artesunate with long-actin blood schizontocides. Ann Trop Med Parasitol 2000;94:23-35.
15. Price RN: Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815-1827.
16. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999;37:105-125.
17. van Agtmael M, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ: Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999;12:151-158.
18. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krodsood S, Silachamroon U, Gathmann I, et al: A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001;64:247-256.
19. van Agtmael M, Gupta V, van der Wösten TH, Rutten J-PB, van Boxtel CJ: Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999;55:405-410.
20. Dyson EH, Proudfoot AT, Prescott LF, Heyworth R: Death and blindness due to overdose of quinine. Br Med J 1985;291:31-33.
21. Goldenberg AM, Wexler LF: Quinine overdose: review toxicity and treatment. Clin Cardiol 1988;11:716-718.
22. Boland ME, Roper SMB, Henry JA: Complications of quinine poisoning. Lancet 1985;1:384-385.
23. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T: Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med 1982;73:564-572.
24. Gilles HM: Management of Severe and Complicated Malaria: A Practical Handbook. Geneva, Switzerland: World Health Organization, 1991. (Follow up: Management of Severe Malaria: A Practical Handbook. 2nd ed. Geneva, Switzerland: World Health Organization, 2000.)
25. World Health Organization: World Health Organisation Model Prescribing Information: Drugs Used in Parasitic Diseases. 2nd ed. Geneva, Switzerland: World Health Organization, 1995.
26. Molyneux M, Fox R: Diagnosis and treatment of malaria in Britain. Br Med J 1993;306:1175-1180.
27. Drugs for parasitic infections. Med Lett Drugs Ther 1995;37:99-108.
28. Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 1996;279:1327-1334.
29. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S: Metabolism of quinine in humans: evidence for the involvement of human CYP3A in the hepatic metabolism of quinine. Br J Clin Pharmacol 1997;43:245-252.
30. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL: The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999;66:454-460.
31. Krishna S, White NJ: Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 1996;30:263-299.
32. Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P: Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol 1986;22:346-350.
33. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S: Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol 1995;40:87-91.
34. Fourcade L, Hovette P, de Pina JJ, Rault JP, Peyron F, Touze JE: Prolonged QT interval and cardiac toxicity due to halofantrine. Med Trop 1995;55:182-183.
35. Nosten F, ter Kuile F, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ: Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993;341:1054-1056.
36. Coyne PE, Ajayi F, Harris J, Wiley T, Worthham D, Cantilena LR: Pharmacodynamics and pharmacokinetics of halofantrine and mefloquine. Clin Pharmacol Ther 1996;59:160.
37. Watt G, Na-Nakorn A, Bateman DN, Plubha N, Mothanaprakoon P, Edstein M, Webster HK: Amplification of quinine cardiac effects by the resistance-reversing agent prochlorperazine in falciparum malaria. Am J Trop Med Hyg 1993;49:645-649.
38. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M: Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995;89:430-433.
39. Toivonen L, Viitasalo M, Siikamaki H, Raatikka M, Pohjola-Sintonen S: Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994;17:403-404.
40. van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, et al: Efficacy of six doses of artemether-lumefantrine (benflumetol) in multi-drug resistant falciparum malaria. Am J Trop Med Hyg 1999;60:936-942.
41. van Agtmael M, Bouchaud O, Malvy D, Delmont J, Danis M, Barette S, et al: The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travelers returning from the tropics to the Netherlands and France. Int J Antimicrob Agents 1999;12:159-169.
42. Kshirsagar NA, Gogtay NJ, Moorthy NS, Garg MR, Dalvi SS, Chogle AR, et al: A randomized, double-blind, parallel group, comparative safety and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute, uncomplicated P. falciparum malaria in adults in India. Am J Trop Med Hyg 2000;62:402-408.
43. Bindschedler M, Lefèvre G, Degen P, Sioufi A: Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg 2002;66:295-300.
44. Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M: Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 2000;56:375-381.
45. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E: An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 2000;94:419-424.
46. Bindschedler M, Degen P, Lu ZL, Jiao XQ, Liu GY, Fan F: Comparative bioavailability of benflumetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects [abstract P-01-96]. Proceedings of the 14th International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, November 17-22, 1996.
47. Colussi D, Parisot C, Legay F, Lefèvre G: Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci 1999;9:9-16.
48. Rimchala P, Karbwang J, Sukontason K, Banmairuroi V, Molunto P, Na-Bangchang K: Pharmacokinetics of quinine in patients with chronic renal failure. Eur J Clin Pharmacol 1996;49:497-501.
49. Pearson S: Quinine toxicity. Emerg Med 1998;10:317-323.
50. van Hensbroek MB, Kwiatkowski D, van den Berg B, Hoek FJ, van Boxtel CJ, Kager PA: Quinine pharmacokinetics in young children with severe malaria. Am J Trop Med Hyg 1996;54:237-242.
51. Souppart C, Gauducheau N, Sandrenan N, Richard F: Development and validation of a high-performance liquid chromatographymass spectrometry assay for the determination of artemether and its dihydroartemisinin metabolite in human plasma. J Chromatogr B; in press.
52. Mansor SM, Navaratnam V, Yahaya N, Nair NK, Wernsdorfer WH, Degen PH: Determination of a new antimalarial drug, benflumetol, in blood plasma by reverse-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1996;682:321-325.
53. Chaulet JF, Robert Y, Prevosto JM, Soares O: Simultaneous determination of chloroquine and quinine in human biological fluids by high-performance liquid chromatography. J Chromatogr 1993;613:303-310.
54. Edstein MD, Prasitthipayong A, Sabchareon A, Chongsuphajaisiddhi T, Webster HK: Simultaneous measurement of quinine and quinidine in human plasma, whole blood, and erythrocytes by high-performance liquid chromatography with fluorescence detection. Ther Drug Monitor 1990;12:493-500.
55. Bazett HC: An analysis of the time relations of electrocardiograms. Heart 1920;7:354-369.
56. Ahnve S: Correction of QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985;109:568-574.
57. Goldsmith RS: Antiprotozoal drugs, in: Katzung BG (ed.), Basic and Clinical Pharmacology. 4th ed. New York: Appleton Lange, 1989.
58. Boulos BM, Short CR, Davies LE: Quinine and quinidine inhibition of pentobarbitone metabolism. Biochem Pharmacol 1970;19:723-732.
59. Suzuki T, Fan Chiang HJ, Yanaura S, Yoshida T, Kuroiwa Y: Enhancement of behavioral effect and acute toxicity of methamphetamine by quinine in rats. Jpn J Pharmacol 1984;35:273-277.
60. Pedersen KE, Madsen JL, Klitgaard NA, Kjaer K, Hvidt S: Effect of quinine on plasma concentrations and renal digoxin clearance. Acta Med Scand 1985;218:229-232.
61. Amabeoku GJ, Chikuni O, Akino C, Mutetwa S: Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers. East Afr Med J 1993;70:90-93.
62. Giao PT, de Vries P: Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001;40:343-373.
63. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ: No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999;61:964-967.
64. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, et al: Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000;94:545-548.
65. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ: Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000;44:697-704.
66. Auprayoon P, Sukontason K, Na-Bangchang K, Banmairuroi V, Molunto P, Karbwang J: Pharmacokinetics of quinine in chronic liver disease. Br J Clin Pharmacol 1995;40:494-497.
67. Na-Bangchang K, Tan-Ariya P, Thanavibul A, Riengchainam S, Shrestha SB, Karbwang J: Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. Int J Clin Pharm Res 1999;19:73-82.